US2016051551A1PendingUtilityA1

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Assignee: NOVARTIS AGPriority: Jan 12, 1998Filed: Oct 20, 2015Published: Feb 25, 2016
Est. expiryJan 12, 2018(expired)· nominal 20-yr term from priority
A61P 37/00A61P 9/10A61P 43/00A61P 9/00A61P 35/00A61P 31/00A61P 29/00A61P 3/10A61P 17/06A61P 17/00C07D 405/14C07D 417/14C07D 405/04A61K 31/517C07D 411/04C07D 417/04C07D 239/94C07D 471/04A61K 31/519
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical formulation comprising the compound of formula

Claims

exact text as granted — not AI-modified
1 . A method of treating bladder cancer in a human or animal subject mammal, comprising administering to said subject an effective amount of the compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt or solvate thereof.

Join the waitlist — get patent alerts

Track US2016051551A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.